Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Free Cash Flow (2016 - 2025)

Iradimed (IRMD) has disclosed Free Cash Flow for 13 consecutive years, with $12.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 201.22% to $12.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $28.9 million, a 17.04% increase, with the full-year FY2024 number at $24.8 million, up 92.37% from a year prior.
  • Free Cash Flow was $12.8 million for Q3 2025 at Iradimed, up from $5.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $12.8 million in Q3 2025 to a low of -$2.9 million in Q2 2023.
  • A 5-year average of $4.0 million and a median of $3.6 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: skyrocketed 392.26% in 2021, then plummeted 308.18% in 2023.
  • Iradimed's Free Cash Flow stood at $3.1 million in 2021, then rose by 0.01% to $3.1 million in 2022, then soared by 235.74% to $10.3 million in 2023, then grew by 1.32% to $10.4 million in 2024, then rose by 23.05% to $12.8 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Free Cash Flow are $12.8 million (Q3 2025), $5.1 million (Q2 2025), and $594624.0 (Q1 2025).